Optimizing the safety of antibody–drug conjugates for patients with solid tumours
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-06-09
DOI
10.1038/s41571-023-00783-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
- (2023) Ursula A. Matulonis et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial
- (2023) Dion Morton et al. JOURNAL OF CLINICAL ONCOLOGY
- Payload diversification: a key step in the development of antibody–drug conjugates
- (2023) Louise Conilh et al. Journal of Hematology & Oncology
- Payload-binding Fab fragments increase the therapeutic index of MMAE antibody-drug conjugates
- (2023) Brandon M. Bordeau et al. MOLECULAR CANCER THERAPEUTICS
- The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules
- (2023) Beatriz G. de la Torre et al. MOLECULES
- Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
- (2023) Toan D. Nguyen et al. Cancers
- Antibody–drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry
- (2023) Yeji Hong et al. ARCHIVES OF PHARMACAL RESEARCH
- Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes
- (2023) Hsuan-Ping Chang et al. Pharmaceutics
- Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours
- (2023) Jian Zhang et al. npj Breast Cancer
- Praluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: an open-label phase 1/2 trial
- (2022) Valentina Boni et al. CLINICAL CANCER RESEARCH
- Clinical pharmacology of the antibody-drug conjugate enfortumab vedotin in advanced urothelial carcinoma and other malignant solid tumors.
- (2022) Mei Tang et al. JOURNAL OF CLINICAL ONCOLOGY
- Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible.
- (2022) Daniel P. Petrylak et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.
- (2022) Yelena Y. Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).
- (2022) Matt D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens.
- (2022) Petros Grivas et al. JOURNAL OF CLINICAL ONCOLOGY
- Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer
- (2022) Paolo Tarantino et al. JAMA Oncology
- Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial
- (2022) Romualdo Barroso-Sousa et al. npj Breast Cancer
- 58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment
- (2022) F. Marmé et al. ANNALS OF ONCOLOGY
- LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial
- (2022) A. Prat et al. ANNALS OF ONCOLOGY
- 166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study
- (2022) P. Schmid et al. ANNALS OF ONCOLOGY
- Abstract GS1-05: Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study
- (2022) Ian Krop et al. CANCER RESEARCH
- Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
- (2022) Eleonora Nicolò et al. CANCER TREATMENT REVIEWS
- Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy
- (2022) Fan Shi et al. DRUG DELIVERY
- Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update
- (2022) Sharon H. Giordano et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical Evaluation of IMGC936, a Next Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors
- (2022) Juniper A. Scribner et al. MOLECULAR CANCER THERAPEUTICS
- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
- (2022) Javier Cortés et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bystander effect of antibody–drug conjugates: fact or fiction?
- (2022) Federica Giugliano et al. Current Oncology Reports
- Potential of antibody–drug conjugates (ADCs) for cancer therapy
- (2022) Hany E. Marei et al. Cancer Cell International
- Phase I Trial of a Novel Anti-HER2 Antibody–Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer
- (2022) Jian Zhang et al. CLINICAL CANCER RESEARCH
- Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC).
- (2022) Fabrice Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer.
- (2022) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).
- (2022) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer.
- (2022) Zefei Jiang et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.
- (2022) Laura Spring et al. JOURNAL OF CLINICAL ONCOLOGY
- TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer.
- (2022) Sara A. Hurvitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Transient Inhibition of Trastuzumab-Tumor Binding to Overcome the "Binding-Site Barrier" and Improve the Efficacy of a Trastuzumab-Gelonin Immunotoxin
- (2022) Ping Chen et al. MOLECULAR CANCER THERAPEUTICS
- Depatuxizumab-mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial
- (2022) Andrew B Lassman et al. NEURO-ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
- (2022) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies
- (2022) C.A. Powell et al. ESMO Open
- Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors
- (2022) Leonid Gibiansky et al. CPT-Pharmacometrics & Systems Pharmacology
- LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial
- (2022) K. Goto et al. ANNALS OF ONCOLOGY
- 605P Population pharmacokinetic (PK) analysis of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer
- (2022) K.N. Moore et al. ANNALS OF ONCOLOGY
- LBA73 Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)
- (2022) J.E. Rosenberg et al. ANNALS OF ONCOLOGY
- The therapeutic window of antibody drug conjugates: A dogma in need of revision
- (2022) Raffaele Colombo et al. CANCER CELL
- Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
- (2022) Christopher J. Hoimes et al. JOURNAL OF CLINICAL ONCOLOGY
- MA13.07 TROPION-Lung02: Initial Results for Datopotamab Deruxtecan Plus Pembrolizumab and Platinum Chemotherapy in Advanced NSCLC
- (2022) B. Levy et al. Journal of Thoracic Oncology
- Antibody Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release
- (2022) Anna Kopp et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies
- (2022) Filip Janku et al. Cancer Immunology Research
- Home monitoring in interstitial lung diseases
- (2022) Marlies S Wijsenbeek et al. Lancet Respiratory Medicine
- Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
- (2022) Adrienne G Waks et al. Journal for ImmunoTherapy of Cancer
- Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
- (2022) Hope S. Rugo et al. npj Breast Cancer
- Treatment‐related adverse events of antibody–drug conjugates in clinical trials: A systematic review and meta‐analysis
- (2022) Youwen Zhu et al. CANCER
- Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
- (2022) Alessandro D Santin et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
- (2022) Kensei Yamaguchi et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
- (2022) Sara A Hurvitz et al. LANCET
- Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis
- (2022) Zhiwen Fu et al. EClinicalMedicine
- Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope
- (2021) Aiko Yamaguchi et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study
- (2021) Fiona Blackhall et al. Journal of Thoracic Oncology
- Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
- (2021) Alexander M. Menzies et al. NATURE MEDICINE
- Unlocking the potential of antibody–drug conjugates for cancer therapy
- (2021) Joshua Z. Drago et al. Nature Reviews Clinical Oncology
- Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
- (2021) Thomas Powles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant T-DM1 versus Trastuzumab in Patients with Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer: Subgroup Analyses from KATHERINE
- (2021) E.P. Mamounas et al. ANNALS OF ONCOLOGY
- Transient competitive inhibition bypasses the binding site barrier to improve tumor penetration of trastuzumab and enhance T-DM1 efficacy
- (2021) Brandon M. Bordeau et al. CANCER RESEARCH
- Visualization of intra-tumor pharmacokinetics of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2 heterogeneous model using phosphor-integrated dots imaging analysis
- (2021) Mikiko Suzuki et al. CLINICAL CANCER RESEARCH
- Model Informed Therapeutic Dose Optimization Strategies for Antibody‐Drug Conjugates (ADCs) in Oncology: What Can We Learn from FDA‐Approved ADCs?
- (2021) Michael Z. Liao et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
- (2021) Scott T. Tagawa et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
- (2021) Robert L Coleman et al. LANCET ONCOLOGY
- The oncology market for antibody–drug conjugates
- (2021) Carolina do Pazo et al. NATURE REVIEWS DRUG DISCOVERY
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
- (2021) A. Bardia et al. ANNALS OF ONCOLOGY
- LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer
- (2021) C. Saura Manich et al. ANNALS OF ONCOLOGY
- RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies.
- (2021) Jiayu Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).
- (2021) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
- (2021) Sara M. Tolaney et al. JOURNAL OF CLINICAL ONCOLOGY
- Stepping forward in antibody-drug conjugate development
- (2021) Yiming Jin et al. PHARMACOLOGY & THERAPEUTICS
- Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance
- (2021) Chisato M. Yamazaki et al. Nature Communications
- Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
- (2021) Laura M. Spring et al. npj Breast Cancer
- Identification of cell surface targets for CAR-T cell therapies and antibody–drug conjugates in breast cancer
- (2021) F. Schettini et al. ESMO Open
- Site-Specific Antibody Conjugation to Engineered Double Cysteine Residues
- (2021) Qun Zhou et al. Pharmaceuticals
- Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies
- (2021) Gabriele Antonarelli et al. Pharmaceuticals
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
- (2021) A. Gennari et al. ANNALS OF ONCOLOGY
- Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
- (2021) Paolo Tarantino et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Factors influencing the choice of monoclonal antibodies for antibody–drug conjugates
- (2021) Md. Mahbub Hasan et al. DRUG DISCOVERY TODAY
- Cellular-Resolution Imaging of Bystander Payload Tissue Penetration from Antibody-Drug Conjugates
- (2021) Eshita Khera et al. MOLECULAR CANCER THERAPEUTICS
- Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
- (2021) Michihiko Aoyama et al. PHARMACEUTICAL RESEARCH
- Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates
- (2021) Paolo Tarantino et al. JAMA Oncology
- Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
- (2020) David M. O'Malley et al. GYNECOLOGIC ONCOLOGY
- Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
- (2020) Shanu Modi et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2-Low Breast Cancer: Pathological and Clinical Landscape
- (2020) Paolo Tarantino et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation
- (2020) Jessica K. Simmons et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- A platform for the generation of site-specific antibody-drug conjugates that allows for selective reduction of engineered cysteines
- (2020) Ruud Coumans et al. BIOCONJUGATE CHEMISTRY
- Beyond thrombosis: the impact of tissue factor signaling in cancer
- (2020) Dusten Unruh et al. Journal of Hematology & Oncology
- Nonclinical Development of Next Generation Site-Specific HER2 Targeting Antibody Drug Conjugate (ARX788) for Breast Cancer Treatment
- (2020) Prathap Nagaraja Shastri et al. MOLECULAR CANCER THERAPEUTICS
- Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
- (2020) Lorenzo Galluzzi et al. Nature Reviews Clinical Oncology
- Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer
- (2020) Javier Cortés et al. JAMA Oncology
- Interstitial pneumonitis related to trastuzumab deruxtecan, a HER2‐targeting antibody drug conjugate, in monkeys
- (2020) Kazuyoshi Kumagai et al. CANCER SCIENCE
- Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
- (2020) Leisha A Emens et al. LANCET ONCOLOGY
- Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors
- (2020) Ophelia Yin et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- An overview of process development for antibody-drug conjugates produced by chemical conjugation technology
- (2020) Yutaka Matsuda et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells
- (2019) Maxine Bauzon et al. OncoImmunology
- Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).
- (2019) Timothy Iveson et al. JOURNAL OF CLINICAL ONCOLOGY
- Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
- (2019) Prathap Kumar Mahalingaiah et al. PHARMACOLOGY & THERAPEUTICS
- Polatuzumab Vedotin: First Global Approval
- (2019) Emma D. Deeks DRUGS
- Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
- (2019) Kenji Tamura et al. LANCET ONCOLOGY
- Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
- (2019) Udai Banerji et al. LANCET ONCOLOGY
- Hydrophilic Sequence-Defined Cross-Linkers for Antibody–Drug Conjugates
- (2019) Joshua A. Walker et al. BIOCONJUGATE CHEMISTRY
- Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology
- (2019) Karen A. Autio et al. CLINICAL CANCER RESEARCH
- Tissue-specific expression of IgG receptors by human macrophages ex vivo
- (2019) Christine W. Bruggeman et al. PLoS One
- Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Kirollos S. Hanna DRUGS
- Daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis
- (2018) Caroline E. Broos et al. EUROPEAN RESPIRATORY JOURNAL
- FGF2 Dual Warhead Conjugate with Monomethyl Auristatin E and α-Amanitin Displays a Cytotoxic Effect towards Cancer Cells Overproducing FGF Receptor 1
- (2018) Karolina Świderska et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors
- (2018) Gentry T. King et al. INVESTIGATIONAL NEW DRUGS
- Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
- (2018) Sara A Hurvitz et al. LANCET ONCOLOGY
- FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33‐Positive Acute Myeloid Leukemia
- (2018) Kelly J. Norsworthy et al. ONCOLOGIST
- Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability
- (2018) D Sussman et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer
- (2018) Virginia F. Borges et al. JAMA Oncology
- Abstract 3914: ZW49, a HER2-targeted biparatopic antibody-drug conjugate for the treatment of HER2-expressing cancers
- (2018) Kevin J. Hamblett et al. CANCER RESEARCH
- Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer
- (2018) Kathleen N. Moore et al. GYNECOLOGIC ONCOLOGY
- Progress in adjuvant systemic therapy for breast cancer
- (2018) Noam F. Pondé et al. Nature Reviews Clinical Oncology
- Human and mouse albumin bind their respective neonatal Fc receptors differently
- (2018) Jeannette Nilsen et al. Scientific Reports
- Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads
- (2018) Amit Kumar et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor–Positive Phase II Randomized Trial—Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET
- (2017) Nadia Harbeck et al. JOURNAL OF CLINICAL ONCOLOGY
- Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
- (2017) Julian Andreev et al. MOLECULAR CANCER THERAPEUTICS
- Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma
- (2016) Cong Wei et al. ANALYTICAL CHEMISTRY
- Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study
- (2016) M. Martin et al. ANNALS OF ONCOLOGY
- Abstract 4914: Auristatin-based antibody drug conjugates activate multiple ER stress response pathways resulting in immunogenic cell death and amplified T-cell responses
- (2016) Anthony Cao et al. CANCER RESEARCH
- Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
- (2016) P. M. Challita-Eid et al. CANCER RESEARCH
- Window of opportunity studies: Do they fulfil our expectations?
- (2016) Sandra Schmitz et al. CANCER TREATMENT REVIEWS
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates
- (2016) Carolin Sellmann et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
- (2016) Heather Donaghy mAbs
- Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63
- (2016) B. E. C. G. de Goeij et al. MOLECULAR CANCER THERAPEUTICS
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells
- (2015) Shin Kan et al. BMC CANCER
- Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer
- (2015) Edgardo Rivera et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Improving target cell specificity using a novel monovalent bispecific IgG design
- (2015) Yariv Mazor et al. mAbs
- Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
- (2014) Dan Lu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors
- (2014) Hiroshi Wakui et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)
- (2014) H. Uppal et al. CLINICAL CANCER RESEARCH
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint
- (2014) Matthew D Hellmann et al. LANCET ONCOLOGY
- A general approach to site-specific antibody drug conjugates
- (2014) Feng Tian et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
- (2013) Hagop Kantarjian et al. CANCER
- Therapeutic targeting of EPH receptors and their ligands
- (2013) Andrew W. Boyd et al. NATURE REVIEWS DRUG DISCOVERY
- Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians
- (2013) X Liu et al. PHARMACOGENOMICS JOURNAL
- Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
- (2012) Christina M. Annunziata et al. INVESTIGATIONAL NEW DRUGS
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer
- (2011) Yun Shin Chun et al. ANNALS OF SURGICAL ONCOLOGY
- Expression of Trop2 Cell Surface Glycoprotein in Normal and Tumor Tissues
- (2011) Lara P. Stepan et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- Pathologic Response after Neoadjuvant Therapy is the Major Determinant of Survival in Patients with Esophageal Cancer
- (2010) Kenneth L. Meredith et al. ANNALS OF SURGICAL ONCOLOGY
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
- (2010) Teemu T. Junttila et al. BREAST CANCER RESEARCH AND TREATMENT
- Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
- (2010) N. M. Okeley et al. CLINICAL CANCER RESEARCH
- Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
- (2010) Anjali Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Balancing the efficacy and toxicity of chemotherapy in colorectal cancer
- (2010) Michael S. Braun et al. Therapeutic Advances in Medical Oncology
- Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection
- (2009) A. G. Polson et al. CANCER RESEARCH
- UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
- (2008) D M Kweekel et al. BRITISH JOURNAL OF CANCER
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started